-
American Bioscience v. Baker Norton, et al DC
- 2:00-cv-09589
- C.D. Cal.
- Judge: Mariana R. Pfaelzer +1
- Filed: 09/07/2000
- Closed: 01/07/2003
- Latest Docket Entry: 01/07/2003
- PACER
- Docket updated daily
1
Plaintiff
3
Defendants
0
Accused
Products
1
Patent-in-Suit
853
Days in
Litigation
-
American Bioscience v. Baker Norton, et al DC
- 2:00-cv-09589
- C.D. Cal.
- Judge: Mariana R. Pfaelzer +1
- Filed: 09/07/2000
- Closed: 01/07/2003
- Latest Docket Entry: 01/07/2003
- PACER
- Docket updated daily
Complaint Unavailable
Cause of Action
Infringement
Market Sector
Biotech and Pharma
Referred Judge
Assigned Judge
Outcome Summary
- Patent Information
-
Validity & Enforceability
Claim # | Claim Text | Outcome |
---|---|---|
31 |
A unit dosage form comprising a vessel containing a sufficient quantity of taxane to allow systemic administration at a dose in the range of about 30 mg/m.sup.2 to about 1000 mg/m.sup.2 over an administration period of less than 3 hours.
|
Invalid (102 and 112)
Entry 58 |
36 |
A taxane-containing formulation suitable for delivery of a dose in the range of about 30 mg/m.sup.2 to about 1000 mg/m.sup.2 with an administration period of less than 3 hrs.
|
Invalid (102 and 112)
Entry 58 |
39 |
A pharmaceutically acceptable formulation of taxane comprising in the range of about 30 mg/m.sup.2 to about 1000 mg/m.sup.2 of taxane, wherein said formulation is useful for the reduction of serum testosterone levels in a subject.
|
Invalid (102 and 112)
Entry 58 |
41 |
A unit dosage form according to claim 31, wherein said quantity of taxane is sufficient to allow systemic administration of a taxane dose of greater than 80 mg/m.sup.2 and up to 700 mg/m.sup.2 over an administration period of less than 3 hours.
|
Invalid (102 and 112)
Entry 58 |
42 |
A formulation according to claim 36, wherein said dose is greater than 80 mg/m.sup.2 and up to 700 mg/m.sup.2.
|
Invalid (102 and 112)
Entry 58 |